AIGH Capital Management LLC Sells 221,280 Shares of Grace Therapeutics, Inc. $GRCE

AIGH Capital Management LLC lowered its position in shares of Grace Therapeutics, Inc. (NASDAQ:GRCE) by 19.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 907,217 shares of the company’s stock after selling 221,280 shares during the period. AIGH Capital Management LLC owned 6.56% of Grace Therapeutics worth $2,699,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Palumbo Wealth Management LLC acquired a new position in Grace Therapeutics in the 2nd quarter valued at $144,000. Institutional investors own 6.08% of the company’s stock.

Grace Therapeutics Stock Up 0.5%

GRCE stock opened at $3.82 on Friday. Grace Therapeutics, Inc. has a 52 week low of $1.75 and a 52 week high of $3.99. The business has a 50-day simple moving average of $3.41 and a 200 day simple moving average of $3.22. The company has a market cap of $59.10 million, a PE ratio of -6.16 and a beta of 0.55.

Grace Therapeutics (NASDAQ:GRCE) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). On average, analysts anticipate that Grace Therapeutics, Inc. will post -1.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GRCE. Wall Street Zen raised shares of Grace Therapeutics to a “hold” rating in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $12.00.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.